Financial Performance - The company's revenue for Q1 2024 was ¥5,135,680,997.86, representing a 6.08% increase compared to ¥4,841,503,352.57 in the same period last year[5] - Net profit attributable to shareholders was ¥83,776,431.42, up 4.90% from ¥79,861,688.20 year-on-year[5] - Total operating revenue for Q1 2024 reached CNY 5,135,680,997.86, an increase of 6.08% compared to CNY 4,841,503,352.57 in the same period last year[22] - Net profit for Q1 2024 was CNY 83,524,409.72, representing a 6.06% increase from CNY 78,600,499.56 in Q1 2023[24] - The total comprehensive income for Q1 2024 was CNY 83,529,584.66, compared to CNY 78,158,785.22 in Q1 2023[25] - Earnings per share (EPS) for Q1 2024 was CNY 0.22, compared to CNY 0.21 in the previous year[25] Cash Flow and Investments - The net cash flow from operating activities decreased by 193.59%, resulting in a negative cash flow of ¥106,133,464.90, primarily due to delayed inventory procurement timing compared to the previous year[8] - Cash flow from operating activities showed a net outflow of CNY 106,133,464.90, a decrease from a net inflow of CNY 113,401,415.76 in the same period last year[25] - Total cash flow from investment activities was -144,025,906.71, compared to -128,637,009.15 in the previous year, indicating an increase in cash outflow by approximately 11.9%[26] - The company paid ¥17,241,000 in cash related to investment activities, a significant increase of 729.48% year-on-year, mainly due to the acquisition of minority shareholder equity in a subsidiary[9] - The company reported a decrease in investment income, with a loss of CNY 3,551,142.87 compared to a loss of CNY 2,582,938.01 in the previous year[22] - The company reported an increase in cash paid for investment activities, totaling 144,083,866.76, compared to 133,011,548.01 in the previous year, marking an increase of approximately 8.3%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,021,181,099.48, an increase of 1.93% from ¥11,793,594,461.35 at the end of the previous year[5] - The company's total liabilities rose to CNY 8,977,951,817.70, compared to CNY 8,816,653,809.23 in the previous year[21] - The company's current liabilities reached CNY 8,179,958,046.31, up from CNY 8,026,157,877.52, indicating an increase of about 1.91%[20] - The balance of accounts receivable financing decreased by 50.47% to ¥17,807,800 from the previous year, mainly due to timely bill endorsements and discounts[8] - The balance of prepaid accounts increased by 39.64% to ¥439,755,800, attributed to increased inventory levels[8] - The company reported a total non-current liabilities of CNY 797,993,771.39, which is a slight increase from CNY 790,495,931.71, reflecting a growth of about 0.63%[20] Cash and Equivalents - Cash and cash equivalents decreased to CNY 458,141,985.69 from CNY 606,302,753.24, representing a decline of approximately 24.4%[19] - The total cash and cash equivalents at the end of the period stood at 308,538,734.69, down from 341,124,938.55 in the previous year, reflecting a decrease of about 9.5%[26] Legal and Recovery Efforts - The company has received a total of CNY 78,005,000 from the bankruptcy estate of Guizhou Dechangxiang Pharmaceutical Co., Ltd., with CNY 5,539,110.00 received by Huaron Yufu and CNY 780,050.00 received by Chengdu Hechuang[14] - The court has ordered the auction of a property for CNY 7,017,000, with the distribution plan pending[16] - The company is actively pursuing legal actions to recover CNY 3,969,730.00 from Guizhou Mingrun Construction Engineering Co., Ltd. and Hechuang Ruida, with a court ruling awarding CNY 3,162,830.00 plus interest[17] - The company aims to enhance its operational efficiency and financial stability through ongoing litigation and asset recovery efforts[16] Research and Development - Research and development expenses increased to CNY 1,217,913.27, up from CNY 769,300.60 year-on-year[22] Audit Status - The first quarter report was not audited, indicating that the financial figures are subject to further review[27]
鹭燕医药(002788) - 2024 Q1 - 季度财报